Leukemia drug shows promise in real-world use for relapsed patients
NCT ID NCT03751072
First seen Mar 23, 2026 · Last updated May 20, 2026 · Updated 10 times
Summary
This study looked at how well blinatumomab worked for 92 adults with B-cell acute lymphoblastic leukemia (ALL) that had come back or was not responding to treatment. The drug helps the body's immune cells attack leukemia cells. Researchers measured how long patients lived, how many achieved remission, and what side effects occurred. The study used data from a French program that gave early access to the drug before it was officially approved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CABANNES-HAMY Aurélie
Paris, 75010, France
Conditions
Explore the condition pages connected to this study.